Eagle Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Eagle Pharmaceuticals, Inc. - overview
Established
2007
Location
Woodcliff Lake, NJ, US
Primary Industry
Pharmaceuticals
About
Eagle Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address critical healthcare needs, primarily within oncology and critical care. Founded in 2007 by Scott Tarriff, Eagle Pharmaceuticals, Inc. is headquartered in Woodcliff Lake, US.
The company specializes in pharmaceutical solutions and has successfully completed 4 deals, including raising USD 50. 25 million in an IPO on February 11, 2014. As of December 2025, the company is led by its CEO, Michael Graves. Eagle Pharmaceuticals, Inc.
specializes in the discovery, development, and marketing of innovative medicines aimed at addressing critical healthcare needs, particularly in oncology and critical care. The company’s key product offerings include BARHEMSYS® (amisulpride) injection and BYFAVO® (remimazolam) for injection, both designed to enhance patient outcomes by providing effective treatment options. BARHEMSYS® is utilized for the treatment of postoperative nausea and vomiting, while BYFAVO® functions as a sedative for procedural sedation, marketed primarily to hospitals and healthcare providers across North America and select international markets. In the most recent fiscal year of 2022, Eagle Pharmaceuticals reported a revenue of USD 316.
61 mn and an EBITDA of USD 93. 45 mn. The company's revenue model is primarily based on direct sales to healthcare providers and institutions, focusing on B2B transactions with negotiated contracts that define pricing and volume commitments. Looking ahead, Eagle Pharmaceuticals plans to expand its product portfolio and is actively developing new medicines targeted at unmet healthcare needs.
The company aims to penetrate additional geographic markets to extend its reach, although specific regions have yet to be disclosed. The recent funding round raised USD 2. 74 mn, which will support these initiatives and enhance operational capabilities. The latest deal in February 2014 provided significant capital to bolster their growth trajectory.
Current Investors
ProQuest Investments
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.eagleus.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Eagle Pharmaceuticals, Inc. - timeline of key events
Eagle Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Sep 30, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 19,099,000 | 66,227,000 | 189,482,000 | 236,707,000 | 213,312,000 | 195,892,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 24.9% | (9.9%) | (8.2%) | - | - | - |
| EBITDA (USD) | (18,653,000) | 2,672,000 | 54,940,000 | 77,959,000 | 40,662,000 | 26,946,000 | - | - | - |
| Operating Income (USD) | (18,757,000) | 2,560,000 | 53,351,000 | 73,990,000 | 36,616,000 | 21,815,000 | - | - | - |
| Operating Margin | (98.2%) | 3.9% | 28.2% | 31.3% | 17.2% | 11.1% | - | - | - |
| % EBITDA Margin | (97.7%) | 4.0% | 29.0% | 32.9% | 19.1% | 13.8% | - | - | - |
| NET Income (USD) | (17,977,000) | 2,571,000 | 81,453,000 | 51,943,000 | 31,903,000 | 14,313,000 | - | - | - |
| % Net Margin | (94.1%) | 3.9% | 43.0% | 21.9% | 15.0% | 7.3% | - | - | - |
Eagle Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.